Saint Germain-en-Laye, France

Ralph Eckenberg

USPTO Granted Patents = 7 

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 44(Granted Patents)


Location History:

  • Germain en Laye, FR (2001 - 2005)
  • St. Germain en Laye, FR (2003 - 2010)
  • Saint Germain en Laye, FR (2004 - 2010)

Company Filing History:


Years Active: 2001-2010

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Ralph Eckenberg: Innovator in Therapeutic Peptides

Introduction

Ralph Eckenberg is a notable inventor based in Saint Germain-en-Laye, France. He has made significant contributions to the field of therapeutic agents, particularly through his work with interleukin-2 (IL-2) peptides. With a total of 7 patents to his name, Eckenberg's innovations are paving the way for advancements in medical treatments.

Latest Patents

Eckenberg's latest patents include a method for inducing selected useful activities of IL-2 in a patient using peptides derived from IL-2. This invention focuses on new peptides and their derivatives, highlighting their potential as therapeutic agents. Another significant patent involves the method of inducing SHC phosphorylation, which activates the SHC/MAPK pathway by administering a peptide of IL-2. This also emphasizes the therapeutic applications of these innovative peptides.

Career Highlights

Eckenberg is affiliated with the prestigious Institut Pasteur, where he continues to conduct research and develop new therapeutic strategies. His work is characterized by a commitment to improving patient outcomes through innovative peptide therapies.

Collaborations

Eckenberg collaborates with esteemed colleagues such as Jacques Theze and Jean-Louis Moreau, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Ralph Eckenberg's contributions to the field of therapeutic peptides demonstrate his dedication to advancing medical science. His innovative patents and collaborations position him as a key figure in the development of new treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…